AR084916A1 - Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas - Google Patents
Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicasInfo
- Publication number
- AR084916A1 AR084916A1 ARP120100213A ARP120100213A AR084916A1 AR 084916 A1 AR084916 A1 AR 084916A1 AR P120100213 A ARP120100213 A AR P120100213A AR P120100213 A ARP120100213 A AR P120100213A AR 084916 A1 AR084916 A1 AR 084916A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- ring
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Compuestos de pirazol caracterizados porque tienen la fórmula (1) ó (2) y sales farmacéuticamente aceptables de los mismos, en los que: Ra y Rb se seleccionan independientemente de: hidrógeno, hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8 o Ra y Rb junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo o Ra y Rb junto con el átomo de carbono al que están unidos forman un anillo de 3 a 8 miembros, en los que dicho anillo puede contener 1 ó 2 heteroátomos seleccionados de O, N y S como miembro del anillo y en los que los miembros del anillo de dicho anillo pueden estar opcionalmente independientemente sustituidos por: hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8; Rc y Rd se seleccionan independientemente de: hidrógeno, hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8 o Rc y Rd junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo o Rc y Rd junto con el átomo de carbono al que están unidos forman un anillo de 3 a 8 miembros, en los que dicho anillo puede contener 1 ó 2 heteroátomos seleccionados de O, N y S como miembro del anillo y en los que los miembros del anillo de dicho anillo pueden estar opcionalmente independientemente sustituidos por: hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8; Y1, Y2, Y3, Y4 e Y5 se seleccionan independientemente de N y CRy, en los que cada Ry se selecciona independientemente de: H, hidroxi, halógeno, ciano, nitro, SF5, C(O)NRfRg, alquilo C1-6, hidroxi-alquilo C1-6, [alcoxi C1-6]alquilo C1-6, cicloalquilo C3-8, haloalquilo C1-6, alcoxi C1-6, [alcoxi C1-6]alcoxi C1-6, haloalcoxi C1-6, cicloalcoxi C3-8, alquilamino C1-6, di-alquilamino C1-6, alquilsulfonilo C1-6, fenilo, fenoxi, heterociclilo de 5 ó 6 miembros y heterocicliloxi de 5 ó 6 miembros, en los que Rf y Rg se seleccionan independientemente entre sí de: H, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo de 5 ó 6 miembros o Rf y Rg junto con el átomo de nitrógeno al que están unidos forman una amina cíclica, que puede comprender un heteroátomo más seleccionado de O, N y S como miembro del anillo; Z se selecciona de O, S y NRz, en el que Rz es H, alquilo C1-6 o bencilo; R1 y R2 independientemente entre sí se seleccionan de: H, halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, -NRfRg, cicloalquilo C3-8, [cicloalquil C3-8]-alquilo C1-6, [cicloalquil C3-8]-alquenilo C2-6, cicloalquenilo C3-8, [cicloalquenil C3-8]alquilo C1-6, [cicloalquenil C3-8]alquenilo C2-6, fenilo, fenil-alquilo C1-6, fenil-alquenilo C2-6, naftilo, naftil-alquilo C1-6, naftil-alquenilo C2-6, heterociclilo, heterociclil-alquilo C1-6 y heterociclil-alquenilo C2-6, en los que los restos alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 en los radicales mencionados R1 y R2 son no sustituidos o soportan al menos un sustituyente seleccionado de: hidroxi, halógeno, ciano, nitro, alcoxi C1-6, haloalcoxi C1-6, alquilamino C1-6, dialquilamino C1-6 y alquilsulfonilo C1-6 y/o en los que dos radicales unidos al mismo átomo de carbono de dichos restos alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 en los radicales mencionados R1 y R2 junto con dicho átomo de carbono pueden formar un grupo carbonilo y en los que los restos cicloalquilo C3-8, cicloalquenilo, fenilo, naftilo y heterociclilo en los radicales mencionados R1 y R2 son no sustituidos o soportan al menos un sustituyente seleccionado de: hidroxi, halógeno, ciano, nitro, alquilo C1-6, cicloalquilo C3-8, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, alquilamino C1-6, di-alquilamino C1-6, alquilsulfonilo C1-6, fenilo y hetarilo de 5 ó 6 miembros y/o en los que dos radicales unidos al mismo átomo de carbono de dichos restos cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo de los radicales R1 y R2 junto con dicho átomo de carbono pueden formar un grupo carbonilo y en los que Rf y Rg se seleccionan independientemente entre sí de: H, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo o Rf y Rg junto con el átomo de nitrógeno al que están unidos forman una amina cíclica, que puede comprender un heteroátomo más seleccionado de O, N y S como miembro del anillo; n es un número entero seleccionado de 0, 1, 2 ó 3; y R3 si están presentes se seleccionan independientemente entre sí de: halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151876 | 2011-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084916A1 true AR084916A1 (es) | 2013-07-10 |
Family
ID=43799503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100213A AR084916A1 (es) | 2011-01-24 | 2012-01-23 | Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8759386B2 (es) |
| EP (1) | EP2668181B1 (es) |
| JP (1) | JP5695216B2 (es) |
| KR (2) | KR101923365B1 (es) |
| CN (4) | CN104961732B (es) |
| AP (1) | AP3343A (es) |
| AR (1) | AR084916A1 (es) |
| AU (1) | AU2012210718B2 (es) |
| BR (1) | BR112013017570B1 (es) |
| CA (1) | CA2825458C (es) |
| CL (1) | CL2013001945A1 (es) |
| CO (1) | CO6801731A2 (es) |
| CY (1) | CY1116012T1 (es) |
| DK (1) | DK2668181T3 (es) |
| EA (1) | EA022559B1 (es) |
| EC (1) | ECSP13012832A (es) |
| ES (1) | ES2529452T3 (es) |
| GE (1) | GEP20156332B (es) |
| HK (3) | HK1215247A1 (es) |
| HR (1) | HRP20150069T1 (es) |
| IL (1) | IL226920A (es) |
| MA (1) | MA34838B1 (es) |
| MX (1) | MX342830B (es) |
| MY (1) | MY163012A (es) |
| PE (1) | PE20140860A1 (es) |
| PH (1) | PH12018501531A1 (es) |
| PL (1) | PL2668181T3 (es) |
| PT (1) | PT2668181E (es) |
| RS (1) | RS53785B1 (es) |
| SG (1) | SG192096A1 (es) |
| SI (1) | SI2668181T1 (es) |
| TN (1) | TN2013000280A1 (es) |
| TW (1) | TWI527809B (es) |
| UA (1) | UA109696C2 (es) |
| UY (1) | UY33873A (es) |
| WO (1) | WO2012101043A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759386B2 (en) * | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| JP5999387B2 (ja) * | 2011-03-25 | 2016-09-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｒｔｈ２拮抗薬としてのピラゾール化合物 |
| US20140148484A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| US20140148492A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Bicyclosubstituted pyrazole compounds for treating hair loss |
| EP3768245A4 (en) * | 2018-03-23 | 2023-10-18 | Palatin Technologies, Inc. | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS OF ADMINISTRATION SPECIFIC TO THE GASTROINTESTINAL TRACT |
| AR117472A1 (es) | 2018-12-21 | 2021-08-11 | Celgene Corp | Inhibidores de tienopiridina de ripk2 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
| AR026414A1 (es) * | 1999-11-10 | 2003-02-12 | Takeda Pharmaceutical | Compuetos heterociclicos de 5 miembros que contienen nitrogeno |
| ES2257616T3 (es) | 2003-04-25 | 2006-08-01 | Actimis Pharmaceuticals, Inc. | Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2. |
| JP2007509104A (ja) * | 2003-10-24 | 2007-04-12 | グラクソ グループ リミテッド | 複素環式化合物 |
| US20080039442A1 (en) * | 2004-12-21 | 2008-02-14 | Devgen Nv | Compounds With Kv4 Ion Channel Activity |
| JP4950542B2 (ja) * | 2006-04-07 | 2012-06-13 | 岩手東芝エレクトロニクス株式会社 | 固体撮像装置およびその製造方法 |
| WO2007141267A1 (en) | 2006-06-06 | 2007-12-13 | Glaxo Group Limited | N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
| JP4469924B2 (ja) * | 2006-11-27 | 2010-06-02 | ファイザー・プロダクツ・インク | ピラゾール類似体 |
| NZ584351A (en) | 2007-09-25 | 2012-03-30 | Actimis Pharmaceuticals Inc | 2-S-benzyl substituted pyrimidines as CRTH2 antagonists |
| ES2383249T3 (es) | 2007-09-25 | 2012-06-19 | Actimis Pharmaceuticals, Inc. | Alquiltiopirimidinas como antagonistas de CRTH2 |
| JP2011088826A (ja) * | 2008-01-31 | 2011-05-06 | Astellas Pharma Inc | 芳香族カルボン酸化合物 |
| US20110190227A1 (en) * | 2008-07-03 | 2011-08-04 | Amira Pharmaceuticals, Inc. | Antagonists of Prostaglandin D2 Receptors |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| EP2393492A1 (en) * | 2009-02-09 | 2011-12-14 | Boehringer Ingelheim International GmbH | New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| SI2528901T1 (sl) * | 2010-01-27 | 2015-10-30 | Boehringer Ingelheim International Gmbh | Pirazolne spojine kot CRTH2 antagonisti |
| WO2012013567A1 (en) * | 2010-07-28 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US8759386B2 (en) * | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
-
2012
- 2012-01-19 US US13/353,621 patent/US8759386B2/en active Active
- 2012-01-19 TW TW101102302A patent/TWI527809B/zh not_active IP Right Cessation
- 2012-01-20 KR KR1020137019577A patent/KR101923365B1/ko active IP Right Grant
- 2012-01-20 CN CN201510362688.2A patent/CN104961732B/zh not_active Expired - Fee Related
- 2012-01-20 MY MYPI2013002719A patent/MY163012A/en unknown
- 2012-01-20 MA MA36130A patent/MA34838B1/fr unknown
- 2012-01-20 WO PCT/EP2012/050830 patent/WO2012101043A1/en active Application Filing
- 2012-01-20 BR BR112013017570-2A patent/BR112013017570B1/pt not_active IP Right Cessation
- 2012-01-20 CN CN201280006303.3A patent/CN103339125B/zh not_active Expired - Fee Related
- 2012-01-20 AU AU2012210718A patent/AU2012210718B2/en not_active Ceased
- 2012-01-20 EP EP12700695.5A patent/EP2668181B1/en active Active
- 2012-01-20 CN CN201710440429.6A patent/CN107011332B/zh not_active Expired - Fee Related
- 2012-01-20 KR KR1020187033824A patent/KR102251939B1/ko active IP Right Grant
- 2012-01-20 RS RS20150037A patent/RS53785B1/en unknown
- 2012-01-20 PE PE2013001586A patent/PE20140860A1/es active IP Right Grant
- 2012-01-20 CA CA2825458A patent/CA2825458C/en active Active
- 2012-01-20 EA EA201300857A patent/EA022559B1/ru not_active IP Right Cessation
- 2012-01-20 PT PT127006955T patent/PT2668181E/pt unknown
- 2012-01-20 JP JP2013549819A patent/JP5695216B2/ja not_active Expired - Fee Related
- 2012-01-20 ES ES12700695.5T patent/ES2529452T3/es active Active
- 2012-01-20 SI SI201230126T patent/SI2668181T1/sl unknown
- 2012-01-20 CN CN201410837969.4A patent/CN104628705B/zh not_active Expired - Fee Related
- 2012-01-20 DK DK12700695.5T patent/DK2668181T3/da active
- 2012-01-20 PL PL12700695T patent/PL2668181T3/pl unknown
- 2012-01-20 SG SG2013056106A patent/SG192096A1/en unknown
- 2012-01-20 GE GEAP201213204A patent/GEP20156332B/en unknown
- 2012-01-20 AP AP2013006942A patent/AP3343A/xx active
- 2012-01-20 MX MX2013008082A patent/MX342830B/es active IP Right Grant
- 2012-01-20 UA UAA201310232A patent/UA109696C2/uk unknown
- 2012-01-23 AR ARP120100213A patent/AR084916A1/es active IP Right Grant
- 2012-01-24 UY UY0001033873A patent/UY33873A/es unknown
-
2013
- 2013-06-13 IL IL226920A patent/IL226920A/en active IP Right Grant
- 2013-06-28 CL CL2013001945A patent/CL2013001945A1/es unknown
- 2013-06-28 TN TNP2013000280A patent/TN2013000280A1/fr unknown
- 2013-07-26 CO CO13177740A patent/CO6801731A2/es active IP Right Grant
- 2013-08-15 EC ECSP13012832 patent/ECSP13012832A/es unknown
- 2013-12-10 HK HK16103130.7A patent/HK1215247A1/zh not_active IP Right Cessation
- 2013-12-10 HK HK15111230.0A patent/HK1210467A1/xx not_active IP Right Cessation
- 2013-12-10 HK HK13113692.9A patent/HK1186183A1/xx not_active IP Right Cessation
-
2015
- 2015-01-20 HR HRP20150069AT patent/HRP20150069T1/hr unknown
- 2015-02-02 CY CY20151100103T patent/CY1116012T1/el unknown
-
2018
- 2018-07-18 PH PH12018501531A patent/PH12018501531A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084916A1 (es) | Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| MX2014000626A (es) | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa. | |
| PE20151596A1 (es) | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio | |
| AR082788A1 (es) | Composiciones pesticidas y procesos de preparacion de los mismos | |
| GT201200346A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| ECSP12012083A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| AR085149A1 (es) | Moduladores del receptor de glucagon | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| EA201891262A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний | |
| ME01185B (me) | Derivati alkaloidnih aminoestara i njihovi ljekoviti preparati | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| ECSP088257A (es) | Derivados de amida | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |